Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le lundi 17 février 2020
Doi : 10.1016/j.jaad.2020.01.019
Health care regulation, the Food and Drug Administration (FDA), and access to medicine : Our experience with dupilumab for children

Chang Ye Wang, MD a, , Rui Rui Chloe Zheng, JD b, Zachary A. Doerrer, BSc c, Anastasia O. Kurta, DO a, Jacob J. Shelley, SJD b, d, Elaine C. Siegfried, MD a
a Department of Dermatology, Saint Louis University, St Louis, Missouri 
b Faculty of Law, University of Western Ontario, London, Ontario, Canada 
c School of Medicine, Saint Louis University, St Louis, Missouri 
d School of Health Studies, University of Western Ontario, London, Ontario, Canada 

Correspondence to: Chang Ye Wang, MD, 1755 S Grand Blvd, St Louis, MO 63104.1755 S Grand BlvdSt LouisMO63104

Abbreviations used : FDA

 Authors Wang and Zheng contributed equally to this work.
 Funding sources: None.
 Conflicts of interest: Dr Siegfried, possibly related: principal investigator clinical trial, consulting fees, and honorarium for Regeneron; consulting fees and honorarium for Sanofi Genzyme; consulting fees for UCB and AbbVie. Unrelated: consulting fees and honorarium for Verrica; consulting fees and Data Safety Monitoring Committees for LEO Pharma and Novan; consulting fees for Pfizer and Pierre Fabre; principal investigator, clinical trial for Janssen; and principal investigator for Lilly. Authors Wang, Zheng, Doerrer, Kurta, and Shelley have no conflicts of interest to declare.
 IRB approval status: The primary data used in this article are obtained from studies approved by the SLU IRB.
 Reprints not available from the authors.

Top of the page

© 2020  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline
You can move this window by clicking on the headline